Hope for pompe patients: could a switch in enzyme therapy slow decline?
NCT ID NCT07652814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether switching to avalglucosidase alfa is safe and more effective for people with late-onset Pompe disease whose condition has worsened on the standard treatment, alglucosidase alfa. Participants receive biweekly infusions of the new drug and are monitored for muscle strength, lung function, and quality of life. The trial includes about 6 people aged 5 to 55 in the Netherlands.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avalglucosidase alfa
What this could lead to
If successful, this could offer a better treatment option for people with late-onset Pompe disease whose condition declines on current enzyme therapy.
What could go wrong
This is a small, early-phase study with only 6 participants, so results may not apply to everyone. The drug may not work better or could cause side effects like infusion reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POMPE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus MC
Rotterdam, 3015 GD, Netherlands